Table 2. Aetiology of HF and discharge medications in the 285 subjects.
| Variable | All (n = 285) | Men (n = 150) | Women (n = 135 |
| Aetiology of HF, n (%) | |||
| Hypertension | 216 (75.8) | 119 (79.3) | 97 (71.9) |
| Dilated cardiomyopathy | 24 (8.4) | 16 (10.7) | 8 (5.9) |
| Cor pulmonale | 16 (5.6) | 9 (6.0) | 7 (5.2) |
| Pericardial diseases | 9 (3.2) | 1 (0.7) | 8 (5.9) |
| Rheumatic heart disease | 7 (2.5) | 4 (2.7) | 3 (2.2) |
| Peripartum cardiomyopathy | 6 (2.1) | 0 (0.0) | 6 (4.4) |
| Thyroid heart disease | 3 (1.1) | 0 (0.6) | 3 (2.2) |
| Ischaemic heart disease | 1 (0.4) | 1 (0.7) | 0 (0.0) |
| Adult congenital heart disease | 1 (0.4) | 0 (0.0) | 1 (0.7) |
| Endomyocardial fibrosis | 2 (6.7) | 0 (0.0) | 2 (0.7) |
| Type of heart failure | |||
| Systolic heart failure (%) | 66.4 | 71.4 | 60.9 |
| Heart failure with normal EF (%) | 33.6 | 28.6 | 39.1 |
| Medications, n (%) | |||
| Loop diuretics | 249 (87.4) | 132 (88.0) | 117 (86.7) |
| Digoxin | 219 (76.8) | 114 (76.0) | 105 (77.8) |
| ACE inhibitors/ARBs | 281 (98.6) | 148 (98.7) | 133 (98.5) |
| Beta-blockers | 56 (19.6) | 35 (23.3) | 21 (15.6) |
| Spironolactone | 247 (86.7) | 133 (87.3) | 116 (85.9) |
| Hydrallazine–isosorbide | 33 (11.7) | 19 (12.9) | 14 (10.4) |
| Amiodarone | 5 (1.8) | 4 (2.7) | 1 (0.7) |